<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------
FORM 8-K
------------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 19, 1999
-------------------------------
ALEXION PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-27756 13-3648318
- ---------------------------- ------------ -------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
25 Science Park, New Haven, CT 06511
- ---------------------------------------- -------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (203) 776-1790
----------------------------
Not Applicable
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 5. OTHER EVENTS
On November 19, 1999, Alexion Pharmaceuticals, Inc. issued the press
release filed herewith as Exhibit 99.1.
On November 30, 1999, Alexion Pharmaceuticals, Inc. filed the press
release filed herewith as Exhibit 99.2.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) EXHIBITS.
99.1 Press Release dated November 19, 1999.
99.2 Press Release dated November 30, 1999.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ALEXION PHARMACEUTICALS, INC.
Date: December 1, 1999 By: /s/ Leonard Bell
-----------------------------------------
Name: Leonard Bell, M.D.
Title: President, Chief Executive
Officer, Secretary and Treasurer
<PAGE>
Exhibit 99.1
FOR IMMEDIATE RELEASE
CONTACTS:
<TABLE>
<S> <C> <C>
Alexion Pharmaceuticals, Inc.
Leonard Bell Noonan/Russo Communications, Inc.
President & CEO Ernie Knewitz (Media) Thomson Financial
(203) 776-1790 Ext.103 (212) 696-4455 Ext. 204 Rhonda Chiger (Investor)
email:[email protected] email: [email protected] (212) 510-9280
</TABLE>
ALEXION PHARMACEUTICALS COMPLETES $42,000,000
FOLLOW-ON PUBLIC STOCK OFFERING
NEW HAVEN, CT, Nov. 19, 1999 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN)
announced today that it completed its follow-on offering of 3,000,000 shares of
common stock at $14.00 per share. US Bancorp Piper Jaffray Inc. served as lead
managing underwriter and Hambrecht & Quist, LLC served as co-managing
underwriter.
The proceeds of this offering will be used to fund clinical and manufacturing
development of 5G1.1, to fund pre-clinical research, drug discovery programs and
clinical and manufacturing development for Alexion's other programs and to fund
other general corporate activities.
Alexion is engaged in the development of products for the treatment of
cardiovascular, autoimmune and neurologic diseases caused by undesired effects
of the human immune system. Alexion's two lead product candidates are 5G1.1-SC,
currently in Phase II trials for the treatment of acute inflammation caused by
cardiopulmonary bypass surgery which is being developed in collaboration with
Procter & Gamble; and 5G1.1, in Phase II trials for the chronic treatment of
rheumatoid arthritis and membranous nephritis.
THIS NEWS RELEASE CONTAINS FORWARD LOOKING STATEMENTS. SUCH STATEMENTS ARE
SUBJECT TO CERTAIN FACTORS WHICH MAY CAUSE ALEXION'S PLANS TO DIFFER OR RESULTS
TO VARY FROM THOSE EXPECTED INCLUDING UNEXPECTED PRE-CLINICAL OR CLINICAL
RESULTS, THE NEED FOR ADDITIONAL RESEARCH AND TESTING, DELAYS IN MANUFACTURING,
ACCESS TO CAPITAL AND FUNDING, DELAYS AND ADVERSE CHANGES IN DEVELOPMENT OF
COMMERCIAL RELATIONSHIPS AND A VARIETY OF RISKS SET FORTH FROM TIME TO TIME IN
ALEXION'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING BUT NOT
LIMITED TO THE RISKS DISCUSSED IN ALEXION'S ANNUAL REPORT ON FORM 10-K FOR THE
YEAR ENDED JULY 31, 1999. ALEXION UNDERTAKES NO OBLIGATION TO PUBLICLY RELEASE
RESULTS OF ANY OF THESE FORWARD LOOKING STATEMENTS WHICH MAY BE MADE TO REFLECT
EVENTS OR CIRCUMSTANCES AFTER THE DATE HEREOF OR TO REFLECT THE OCCURRENCE OF
UNANTICIPATED EVENTS.
###
EDITOR'S NOTE: This release is available on the Internet at
http://www.noonanrusso.com.
- ---------------------------
<PAGE>
Exhibit 99.2
FOR IMMEDIATE RELEASE
CONTACTS:
<TABLE>
<S> <C> <C>
Alexion Pharmaceuticals, Inc.
Leonard Bell Noonan/Russo Communications, Inc.
President & CEO Ernie Knewitz (Media) Thomson Financial
(203) 776-1790 Ext.103 (212) 696-4455 Ext. 204 Rhonda Chiger (Investor)
email:[email protected] email: [email protected] (212) 510-9280
</TABLE>
ALEXION PHARMACEUTICALS OVERALLOTMENT OPTION EXERCISED
RAISING AN ADDITIONAL $5.8 MILLION IN ITS FOLLOW-ON PUBLIC
STOCK OFFERING
-- Brings Total Raised in its Recent Offering to $47.8 Million --
NEW HAVEN, CT, Nov. 30, 1999 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN)
today announced that the underwriters of its recently completed public offering
have exercised their overallotment option and have purchased an additional
415,000 shares of common stock. Exercising this option brings the total raised
from the recent offering to $47.8 million. US Bancorp Piper Jaffray Inc. served
as lead managing underwriter and Hambrecht & Quist LLC served as co-managing
underwriter.
The proceeds of this offering will be used to fund clinical and manufacturing
development of 5G1.1, pre-clinical research, drug discovery programs and
clinical and manufacturing development for Alexion's other programs as well as
to fund other general corporate activities.
Alexion is engaged in the development of products for the treatment of
cardiovascular, autoimmune and neurologic diseases caused by undesired effects
of the human immune system. Alexion's two lead product candidates are 5G1.1-SC,
currently in Phase II trials for the treatment of acute inflammation caused by
cardiopulmonary bypass surgery which is being developed in collaboration with
Procter & Gamble; and 5G1.1, in Phase II trials for the chronic treatment of
rheumatoid arthritis and membranous nephritis. This press release and further
information about Alexion Pharmaceuticals, Inc. can be found on the World Wide
Web at: HTTP://WWW.ALEXIONPHARM.COM.
THIS NEWS RELEASE CONTAINS FORWARD LOOKING STATEMENTS. SUCH STATEMENTS ARE
SUBJECT TO CERTAIN FACTORS WHICH MAY CAUSE ALEXION'S PLANS TO DIFFER OR RESULTS
TO VARY FROM THOSE EXPECTED INCLUDING UNEXPECTED PRE-CLINICAL OR CLINICAL
RESULTS, THE NEED FOR ADDITIONAL RESEARCH AND TESTING, DELAYS IN MANUFACTURING,
ACCESS TO CAPITAL AND FUNDING, DELAYS AND ADVERSE CHANGES IN DEVELOPMENT OF
COMMERCIAL RELATIONSHIPS AND A VARIETY OF RISKS SET FORTH FROM TIME TO TIME IN
ALEXION'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING BUT NOT
LIMITED TO THE RISKS DISCUSSED IN ALEXION'S ANNUAL REPORT ON FORM 10-K FOR THE
YEAR ENDED JULY 31, 1999. ALEXION UNDERTAKES NO OBLIGATION TO PUBLICLY RELEASE
RESULTS OF ANY OF THESE FORWARD LOOKING STATEMENTS WHICH MAY BE MADE TO REFLECT
EVENTS OR CIRCUMSTANCES AFTER THE DATE HEREOF OR TO REFLECT THE OCCURRENCE OF
UNANTICIPATED EVENTS.
# # #
